{"product_id":"carboplatin-injection-450-mg-45-ml-multi-dose-vial-45-ml-preservative-free-rx","title":"Carboplatin Injection 450 mg \/ 45 mL Multi-dose Vial 45 mL, Preservative Free (RX)","description":"\u003ch1\u003eCarboplatin Injection 450 mg\/45 mL (Multi-dose vial, Preservative-Free)\u003c\/h1\u003e\n\u003cp\u003e\u003cspan class=\"VODHU pdMy8\"\u003eCarboplatin injection is a platinum-based chemotherapy (antineoplastic) drug. It is supplied as a sterile, preservative-free aqueous solution (10 mg carboplatin per mL) in a multi-dose vial. Each 45 mL vial contains 450 mg of carboplatin and 10 mg mannitol per mL (mannitol is an inert stabilizer). The solution is colorless to pale yellow and is formulated for intravenous use (no preservatives are added)\u003c\/span\u003e.\u003c\/p\u003e\n\u003ch2\u003e\u003cspan class=\"VODHU pdMy8\"\u003eUses:\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan class=\"VODHU pdMy8\"\u003e Carboplatin is primarily used to treat ovarian cancer. It is indicated for the \u003cstrong\u003efirst-line (initial) treatment of advanced ovarian carcinoma\u003c\/strong\u003e in established combination with other chemotherapeutic agents (for example, carboplatin plus cyclophosphamide). It is also indicated for \u003cstrong\u003epalliative treatment of recurrent ovarian cancer\u003c\/strong\u003e in patients who have received prior chemotherapy (including those who relapsed after cisplatin therapy). (In practice, carboplatin is often given with other agents such as paclitaxel in gynecologic cancers.) Physicians may also use carboplatin off-label for other tumors (e.g. lung, head and neck, etc.), but the main approved use is ovarian carcinoma.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan class=\"VODHU pdMy8\"\u003eHow to Use:\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan class=\"VODHU pdMy8\"\u003eCarboplatin injection is given by slow intravenous infusion under healthcare supervision. The drug is typically infused over at least 15 minutes (often longer). Treatment cycles are usually repeated every 3–4 weeks, as determined by patient response and blood counts. The dose is personalized based on body surface area and kidney function, often calculated by the Calvert formula: dose (mg) = AUC × (GFR + 25), where AUC is the target area-under-curve. Carboplatin solution is typically further diluted in IV fluid (for example, 5% dextrose or normal saline) for infusion. Since no preservative is present, the prepared solution should be used within 8 hours of dilution and any unused portion discarded. (Unlike cisplatin, routine hydration or forced diuresis is generally not required during carboplatin administration \u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003eCarboplatin vs Cisplatin\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eMechanism:\u003c\/strong\u003e Both carboplatin and cisplatin are platinum(II) coordination compounds that form DNA cross-links and inhibit DNA synthesis in cancer cells. Carboplatin is a derivative of cisplatin with similar action but different side-effect profiles.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eEfficacy:\u003c\/strong\u003e In ovarian cancer trials, carboplatin (with cyclophosphamide) achieved survival outcomes equivalent to cisplatin combinations. This means carboplatin is generally as effective as cisplatin for that indication.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eToxicity differences:\u003c\/strong\u003e Carboplatin causes \u003cstrong\u003eless kidney (nephro-) and nerve (neuro-) toxicity\u003c\/strong\u003e than cisplatin. Cisplatin is highly nephrotoxic and emetogenic (causes severe nausea\/vomiting), whereas carboplatin has milder kidney effects and is better tolerated (causing less nausea). Conversely, carboplatin produces \u003cstrong\u003emore bone marrow suppression\u003c\/strong\u003e (especially thrombocytopenia) than cisplatin. For example, treatment with carboplatin often requires careful monitoring of blood counts and may cause significant anemia or bleeding risk, while cisplatin causes these effects to a lesser extent. Carboplatin’s peripheral neuropathy and hearing effects are also generally milder than those of cisplatin.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eSide Effects\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eHematologic:\u003c\/strong\u003e The most common toxic effect is bone marrow suppression. Carboplatin frequently causes \u003cstrong\u003eanemia, leukopenia, and thrombocytopenia.\u003c\/strong\u003e This can lead to fatigue, infection or bleeding; blood counts must be checked before each cycle. (In fact, myelosuppression is dose-limiting with carboplatin.)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eGastrointestinal:\u003c\/strong\u003e Nausea and vomiting are fairly common (though typically less severe than with cisplatin). Diarrhea and loss of appetite (anorexia) may also occur.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eNeurologic:\u003c\/strong\u003e Peripheral neuropathy (tingling, numbness or burning in the hands and feet) can occur. Notably, the incidence of serious neuropathy is relatively low, but risk increases with cumulative doses or prior cisplatin use.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eHair and General:\u003c\/strong\u003e Temporary hair loss (alopecia) is possible. Other common effects include fatigue and general weakness.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eHypersensitivity:\u003c\/strong\u003e Allergic (hypersensitivity) reactions can occur, sometimes acutely during infusion. Symptoms range from mild rash to severe anaphylaxis (hives, difficulty breathing, swelling of face\/lips). Monitoring during infusion is important.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eRenal\/Ototoxicity:\u003c\/strong\u003e Although less than with cisplatin, carboplatin can still affect kidneys and hearing. Mild kidney function changes are common (↑ BUN\/creatinine in some patients) and ~25% incidence of nephrotoxicity has been reported. Hearing impairment (tinnitus or hearing loss) occurs in a minority of patients (e.g. ~15%). Electrolyte disturbances (↓Mg, ↓K) may also occur.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eOther:\u003c\/strong\u003e Carboplatin may also cause elevated liver enzymes, fever, and local injection-site reactions. Patients are usually given antiemetic and other supportive medications to manage side effects.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eAlways follow the prescribing information and your medical team’s instructions. This summary is not exhaustive; patients should consult their oncologist or pharmacist for personalized advice on carboplatin therapy.\u003c\/p\u003e\n\u003cp\u003eBrand: Pfizer Hospira\u003cbr\u003eSize: 450mg \/ 45 mL\u003cbr\u003eNDC: 61703-0339-50\u003cbr\u003eUPC: 361703-339508\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003eBuy Carboplatin for Injection 450mg \/ 45 mL online at Mountainside Medical Equipment.\u003c\/p\u003e\n\u003c!-- Microdata markup added by Google Structured Data Markup Helper. --\u003e","brand":"Pfizer Injectables","offers":[{"title":"Default Title","offer_id":68250402848980,"sku":"jil1793471151404","price":91.59,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0834\/2028\/3092\/files\/carboplatin-injection-450-mg-45-ml-multi-dose-vial-45-ml-preservative-free-rx_1.jpg?v=1793471173","url":"https:\/\/samleashset.shop\/products\/carboplatin-injection-450-mg-45-ml-multi-dose-vial-45-ml-preservative-free-rx","provider":"My Store","version":"1.0","type":"link"}